Nilotinib

Nilotinib Reactions 1680, p252 - 2 Dec 2017 Cutaneous and hepatic toxicities: 2 case reports In a cohort study, wherein patients were enrolled in a prospective as well as retrospective manner, two patients [ages and sexes not stated] were described, who developed hepatic and cutaneous toxicities during treatment with nilotinib. The patients, who had a history of chronic myeloid leukaemia, were started on nilotinib at an initial daily dose 600mg [routes not stated]. Subsequently, one of the two patients developed grade 4 hepatic toxicity, and other patient developed grade 4 cutaneous toxicity [durations of treatments to reactions onsets and outcomes not stated]. Author comment: "[I]n 2 cases toxicity was of grade 4 (one patient with hepatic toxicity, another one with cutaneous toxicity)." Galimberti S, et al. The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia. Oncotarget 8: 88021-88033, No. 50, 30 Sep 2017. Available from: URL: http://doi.org/10.18632/ oncotarget.21406 - Italy 803285089 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Nilotinib

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/nilotinib-YECame0SJf
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-39183-1
Publisher site
See Article on Publisher Site

Abstract

Reactions 1680, p252 - 2 Dec 2017 Cutaneous and hepatic toxicities: 2 case reports In a cohort study, wherein patients were enrolled in a prospective as well as retrospective manner, two patients [ages and sexes not stated] were described, who developed hepatic and cutaneous toxicities during treatment with nilotinib. The patients, who had a history of chronic myeloid leukaemia, were started on nilotinib at an initial daily dose 600mg [routes not stated]. Subsequently, one of the two patients developed grade 4 hepatic toxicity, and other patient developed grade 4 cutaneous toxicity [durations of treatments to reactions onsets and outcomes not stated]. Author comment: "[I]n 2 cases toxicity was of grade 4 (one patient with hepatic toxicity, another one with cutaneous toxicity)." Galimberti S, et al. The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia. Oncotarget 8: 88021-88033, No. 50, 30 Sep 2017. Available from: URL: http://doi.org/10.18632/ oncotarget.21406 - Italy 803285089 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680

Journal

Reactions WeeklySpringer Journals

Published: Dec 2, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve Freelancer

DeepDyve Pro

Price
FREE
$49/month

$360/year
Save searches from
Google Scholar,
PubMed
Create lists to
organize your research
Export lists, citations
Read DeepDyve articles
Abstract access only
Unlimited access to over
18 million full-text articles
Print
20 pages/month
PDF Discount
20% off